EXHIBIT 99.1 Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update BOSTON, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical- stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today reported second quarter 2025 financial results and provided a business update on its clinical and pre-clinical programs. "Following our previous announcement that the tovecimig Phase 2/3 trial met ...